Table 1.
Features and outcome of hepatitis C virus + patients with aggressive B-cell non-Hodgkin’s lymphoma treated with chemotherapy and immunochemotherapy
| Author | Year | HCV + patients1 | Histology | Study | Therapy | Severe HT (%) | Poor prognostic factors | ORR (%) | PFS | OS |
| Visco et al[6] | 2006 | 132 | DLBCL | Multicenter, retrospective | CHOP-like (85%) | 15 | Hepatic dysfunction | 93 | 51% (5 yr) | 72% (5 yr) |
| R-CHOP-like (26%) | HBV co-infection | |||||||||
| High IPI | ||||||||||
| Advanced stage | ||||||||||
| Nodal origin | ||||||||||
| Besson et al[13] | 2006 | 26 | DLBCL | Case control, retrospective | Intensified CHT, no Rituximab | 45 | Advanced stage | 72 | - | 56% (5 yr) |
| High IPI | ||||||||||
| Arcaini et al[9] | 2010 | 101 | DLBCL | Retrospective series | CHOP-like | 15 | HCV genotype 1 | 77 | 43% (5 yr) | 68% (5 yr) |
| R-CHOP-like (23%) | HT during CHT | |||||||||
| Marignani et al[10] | 2011 | 8 | DLBCL = 7 | Retrospective series | R-CHOP-like | 28 | NE | 80 | 70% (4 yr) | 80% (4 yr) |
| BL = 1 | ||||||||||
| Ennishi et al[11] | 2010 | 131 | DLBCL | Retrospective series | R-CHOP-like | 27 | Hepatic dysfunction | - | 69% (3 yr) | 75% (3 yr) |
| Age | ||||||||||
| High IPI | ||||||||||
| Advanced stage |
1
Number of hepatitis C virus (HCV) + patients treated with curative intent. NE: Not evaluable; PFS: Progression-free survival; OS: Overall survival; HT: Hepatic toxicity; CHT: Chemotherapy; IPI: International Prognostic Index.